We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > LCB

News List

SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences B3Cnewswire
November 17, 2021
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc...
Iksuda, LegoChem Expand ADC Alliance contractpharma
June 23, 2021
Grants Iksuda access to LegoChem's next generation ADC platform for up to six targets.
WuXi XDC and LegoChem Ink ADC Agreement contractpharma
June 15, 2021
WuXi XDC, a global CDMO providing end-to-end bioconjugates services, and LegoChem Biosciences (LCB), signed a Memorandum of Understanding (MOU) for a partnership in development and manufacturing of antibody-drug conjugates (ADCs).